Brainstorm Cell Therapeutics Inc (BCLI) Trading Down 6.5%

Separately, Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price (down previously from $14.00) on shares of Brainstorm Cell Therapeutics in a research note ... such as Amyotrophic Lateral Sclerosis (NASDAQ:BCLI), Multiple Sclerosis ...